Understanding ocular comfort differences between 0.7% olopatadine and 0.3% pheniramine maleate/0.025% naphazoline hydrochloride eye drops.

Autor:	Lievens C; Southern College of Optometry, Memphis, TN, USA., Pucker AD; Department of Optometry & Vision Science, University of Alabama at Birmingham, Birmingham, AL, USA., McGwin G; Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA., Logan A; Department of Optometry & Vision Science, University of Alabama at Birmingham, Birmingham, AL, USA., Franklin Q; Department of Optometry & Vision Science, University of Alabama at Birmingham, Birmingham, AL, USA., Brafford R; Southern College of Optometry, Memphis, TN, USA., Hogan C; Southern College of Optometry, Memphis, TN, USA., Kelley LR; Southern College of Optometry, Memphis, TN, USA., Christensen M; Southern College of Optometry, Memphis, TN, USA.
Jazyk:	angličtina
Zdroj:	Clinical & experimental optometry [Clin Exp Optom] 2023 Jul; Vol. 106 (5), pp. 498-502. Date of Electronic Publication: 2022 Jul 10.
DOI:	10.1080/08164622.2022.2090231
Abstrakt:	Clinical Relevance: This study found 0.7% olopatadine (Pataday Once Daily Relief Extra Strength) eye drops to provide better initial comfort than 0.3% pheniramine maleate/0.025% naphazoline hydrochloride (VISINE® Allergy Eye Relief Multi-Action Antihistamine and Redness Reliever) eye drops suggesting that patients may comply better with the Pataday than VISINE. Background: To compare the ocular comfort at instillation of Pataday and VISINE allergy eye drops. Methods: Minimally symptomatic participants were recruited based upon Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire scores (≤3 units); they also had minimal between-eye inter-ocular comfort differences as judged by visual analogue scale scores (VAS; ≤7 units). Baseline comfort was evaluated by eye with a VAS. One drop of Pataday or VISINE was then applied to the right eye with the alternative drop being applied to the left eye. The same VAS evaluated comfort by eye at drop instillation, and then at 30 seconds, 1 minute, and 2 minutes post-instillation. Drop experience was also evaluated with Likert questions. LogMAR visual acuities and bulbar conjunctival redness were evaluated pre- and post-drop instillation. Results: A total of 159 participants were recruited (mean ± SD age = 26.2 ± 7.5). The VAS found that eyes treated with Pataday were significantly more comfortable at instillation than eyes treated with VISINE. Likert questions indicated that participants significantly preferred Pataday drops compared to the VISINE drops at instillation with regards to overall eye comfort, eye stinging, eye burning, and foreign body sensation. There were no between drop differences in visual acuity, though eyes treated with VISINE were less red than eyes treated with Pataday. Conclusions: Topically applied Pataday drops were more comfortable than VISINE drops.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu